Ganitumab: Phase III started

Takeda began the Japanese portion of a double-blind, international Phase III trial comparing 12 and 20 mg/kg IV ganitumab given on days 1 and 15 of a 28-day cycle plus 1,000 mg/m 2 IV gemcitabine give...